MST1R
ENSG00000164078
Target class
Kinase
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
4
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Target name
- MST1R
- Gene name
- Macrophage stimulating 1 receptor
- Gene symbol
- MST1R
- Protein name
- Macrophage-stimulating protein receptor (MSP receptor) (EC 2.7.10.1) (CDw136) (Protein-tyrosine kinase 8) (p185-Ron) (CD antigen CD136) [Cleaved into: Macrophage-stimulating protein receptor alpha chain; Macrophage-stimulating protein receptor beta chain]
- CDw136
- CD136
- RON
- PTK8
- SEA
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|CD molecules|IPT domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 33
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 35.5
- Tissue specificity (Gini)
- 0.7
- Tissue specificity (tau)
- 0.881
- KEGG gene identifiers
- hsa:4486
- Reactome pathways
- R-HSA-8852405
- Protein interaction confidence
- 0.808846
- Protein interaction partners
- 13
- End position
- 49906130
- Start position
- 49886902
- Chromosome
- 3
- Strand
- Reverse
- Membrane
- Single-pass type I membrane protein.
- Cytosol
- Tissue specificity (tau)
- 0.881393
- Expression inequality (Gini)
- 0.700326
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)
- 35.5
- Skin - Not Sun Exposed (Suprapubic)
- 33.16
- Stomach
- 25.62
- Colon - Transverse
- 23.11
- Small Intestine - Terminal Ileum
- 19.79
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)35.5
- Skin - Not Sun Exposed (Suprapubic)33.16
- Stomach25.62
- Colon - Transverse23.11
- Small Intestine - Terminal Ileum19.79
- Esophagus - Mucosa14.82
- Vagina14.28
- Lung12.21
- Testis11.49
- Minor Salivary Gland5.68
- Thyroid4.92
- Adipose - Visceral (Omentum)4
- Prostate3.6
- Cervix - Endocervix3.03
- Colon - Sigmoid3.02
- Fallopian Tube2.95
- Esophagus - Gastroesophageal Junction2.94
- Esophagus - Muscularis2.85
- Bladder2.81
- Breast - Mammary Tissue2.68
- Pituitary2.47
- Artery - Aorta2.46
- Pancreas2.17
- Kidney - Medulla1.97
- Uterus1.74
And 29 more, listed on the interactive page.
- GO:0006952
- GO:0007165
- GO:0007338
- GO:0008284
- GO:0009615
- GO:0043406
- GO:0051897
- GO:0005886
- GO:0009986
- GO:0005011
- GO:0005515
- GO:0019899
Related records
Trials (408)
- -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
- A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
- A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
- A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
- A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
- A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma
- A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
- A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab
- A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
- A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
- A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
- A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
- A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
- A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Drugs (9)
- BMS-777607
- Cabozantinib
- Crizotinib Macrophage-stimulating protein receptor inhibitor
- Glesatinib Macrophage-stimulating protein receptor inhibitor
- Merestinib
- MK-2461
- MK-8033 Macrophage-stimulating protein receptor inhibitor
- Narnatumab Macrophage-stimulating protein receptor inhibitor
- XL-999